Share ownership Biogen Inc.

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-09-12 pm EDT			5-day change	1st Jan Change
197.89 ^USD	-0.60%		-3.44%	-23.53%

01:32pm	Biogen Inc. Announces Elects Lloyd B. Minor and Sir Menelas Pangalos as Directors, Effective October 1, 2024 and January 1, 2025, Respectively	CI
Sep. 10	C4 Therapeutics Delivers Final Development Candidate Under Biogen Deal	MT

Share class: Biogen Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	169,461,642	145,418,405 ( 85.81 %)	23,800,000 ( 14.04 %)	85.81 %

Major shareholders: Biogen Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 11.40 %	16,600,163	11.40 %	3 399 M $
PRIMECAP Management Co. 11.22 %	16,338,294	11.22 %	3 345 M $
BlackRock Advisors LLC 7.259 %	10,573,792	7.259 %	2 165 M $
State Street Corp. 4.872 %	7,096,018	4.872 %	1 453 M $
T. Rowe Price Investment Management, Inc. 3.899 %	5,678,859	3.899 %	1 163 M $
Wellington Trust Co., NA 3.547 %	5,166,491	3.547 %	1 058 M $
JPMorgan Investment Management, Inc. 3.235 %	4,712,350	3.235 %	965 M $
BlackRock Life Ltd. 2.527 %	3,681,440	2.527 %	754 M $
Geode Capital Management LLC 2.448 %	3,565,965	2.448 %	730 M $
Norges Bank (13F) 1.427 %	2,078,745	1.427 %	426 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Bram Bradesco Asset Management S/A DTVM 0.000003 %	30	0.000003 %	1 003 $

Breakdown by shareholder type

Institutional	71.50%
Other	12.23%
State Street Corp.	4.87%
Schweizerische Nationalbank	0.30%
Sumitomo Mitsui Trust Holdings, Inc.	0.25%
Governments	0.16%
Polar Capital Holdings Plc	0.15%
Individuals	0.15%
SEI Investments Co.	0.12%
Manulife Financial Corp.	0.09%
Banco Bilbao Vizcaya Argentaria SA	0.08%
Swedbank AB	0.07%
Zurich Insurance Group AG	0.07%
Skandinaviska Enskilda Banken AB	0.06%
Corebridge Financial, Inc.	0.03%
ING Groep NV	0.02%
Banque Cantonale Vaudoise	0.01%
Meitav Investment House Ltd.	0.01%
The Bank of Nova Scotia	0.01%
Fiera Capital Corp.	0.01%
Unknown	9.81%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	70.36%
United Kingdom	8.71%
Canada	2.72%
Norway	1.60%
France	1.10%
Switzerland	1.05%
Australia	0.88%
Sweden	0.56%
Japan	0.56%
Spain	0.35%
South Korea	0.31%
Luxembourg	0.28%
Netherlands	0.26%
Italy	0.18%
Czech Republic	0.16%
Ireland	0.16%
Individuals	0.15%
Denmark	0.12%
Germany	0.12%
Finland	0.10%
Belgium	0.08%
China	0.07%
Austria	0.07%
New Zealand	0.06%
Israel	0.05%
Singapore	0.04%
India	0.03%
Taiwan	0.01%
Slovenia	0.01%
Hong Kong	0.01%
Mexico	0.01%
South Africa	0.01%

Based on 1000 largest holdings

Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (17,2%) ; - other (9,1%): primarily revenues from partnership agreements.

Employees

7,570

Sector

Pharmaceuticals

Calendar

2024-10-21 - Q3 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company